All In Biotech

NDA 208716 · Eli Lilly and CO

Verzenio

Abemaciclib · Oral · Kinase Inhibitor

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 28, 2017

Approved uses

10

Original approval plus efficacy supplements

Registered trials

248

32 Phase 3, 85 recruiting

FAERS reports

21,145

10,932 serious, 1,481 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2026.

VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) in combination with imlunestrant for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. ( 1.2 , 2.1 ) as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or...

Mechanism: Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • VERZENIO · ABEMACICLIB 200MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 100MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 150MG · TABLET, ORAL · Prescription
  • VERZENIO · ABEMACICLIB 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abemaciclib" as an intervention, any sponsor and status, largest first.

All 248 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,577
  • fatigue2,834
  • nausea2,345
  • vomiting1,196
  • malignant neoplasm progression1,148
  • decreased appetite1,021
  • asthenia941
  • death811
  • constipation767
  • white blood cell count decreased761
  • drug ineffective752
  • abdominal pain upper735

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20142
20154
20164
201725
2018850
20191,657
20201,648
20211,496
20222,192
20232,788
20243,399
20253,735
20263,345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Verzenio (Abemaciclib)

2024 spending

$1.06B

Beneficiaries

11,239

71,933 claims

Per beneficiary

$94,026

$268.49 per unit

View as table
YearSpending
2020$286,188,073
2021$324,570,465
2022$474,171,738
2023$756,850,867
2024$1,056,757,309

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 164 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.